Laurus Labs Limited — Updates, 25-07-2025: Press Release

Laurus Labs reports robust Q1 FY26 results with Revenues at ₹1,570 Cr, up 31% YoY. EBITDA soared 127% to ₹389 Cr, expanding margins to 24.8%. Net Profit jumped 1154% to ₹163 Cr. This strong performance was largely driven by the CDMO business, which grew 103% to ₹522 Cr, supported by new manufacturing assets and NCE deliveries. The Generics business also contributed, growing 12% with FDF segment up 50%. The company is expanding future capabilities by commencing construction of new Gene/ADC and Microbial fermentation facilities.